| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10238645 | BAUSCH | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
Aug, 2029
(5 years from now) | |
| US8598196 | BAUSCH | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
Aug, 2029
(5 years from now) | |
| US8222270 | BAUSCH | 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod |
Dec, 2029
(5 years from now) | |
| US8236816 | BAUSCH | 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod |
Dec, 2029
(5 years from now) | |
| US10238644 | BAUSCH | 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
Dec, 2029
(5 years from now) | |
| US11318130 | BAUSCH | 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
Dec, 2029
(5 years from now) | |
| US8299109 | BAUSCH | Method of treating actinic keratosis with 3.75% imiquimod cream |
Dec, 2029
(5 years from now) | |
| US11202752 | BAUSCH | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
Apr, 2030
(6 years from now) | |
| US10918635 | BAUSCH | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
Apr, 2030
(6 years from now) | |
Zyclara is owned by Bausch.
Zyclara contains Imiquimod.
Zyclara has a total of 9 drug patents out of which 0 drug patents have expired.
Zyclara was authorised for market use on 15 July, 2011.
Zyclara is available in cream;topical dosage forms.
Zyclara can be used as treatment of genital warts, treatment of perianal warts, treatment of actinic keratosis.
The generics of Zyclara are possible to be released after 30 April, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 25, 2013 |
| New Indication(I-636) | Mar 24, 2014 |
| New Strength(NS) | Jul 15, 2014 |
Drugs and Companies using IMIQUIMOD ingredient
Market Authorisation Date: 15 July, 2011
Treatment: Treatment of perianal warts; Treatment of actinic keratosis; Treatment of genital warts
Dosage: CREAM;TOPICAL
ZYCLARA family patents
